Literature DB >> 21116659

Effect of divided supplementation of remifentanil on seizure duration and hemodynamic responses during electroconvulsive therapy under propofol anesthesia.

Kohki Nishikawa1, Misako Higuchi, Toshiya Kawagishi, Yuki Shimodate, Michiaki Yamakage.   

Abstract

PURPOSE: Although a reduced dose of propofol combined with remifentanil is often used in anesthesia for electroconvulsive therapy (ECT), there have been few studies in which the optimal technique for injection of remifentanil was examined in detail. The aim of this study was to evaluate the effects of single and divided injection of remifentanil combined with propofol on seizure duration and hemodynamic responses during ECT.
METHODS: Twenty-six ASA I-II patients were enrolled in this study and received a total of 78 ECTs. Each patient received propofol 1.2 mg/kg (group P), remifentanil 1 μg/kg followed by propofol 0.5 mg/kg (group R1), and remifentanil 1 μg/kg followed by propofol 0.5 mg/kg and thereafter remifentanil 2 μg/kg (group R2). Succinylcholine 1 mg/kg was used for muscle paralysis after loss of consciousness.
RESULTS: Although mean motor seizure durations were significantly longer in groups R1 and R2 than in group P (P < 0.05), they were similar in groups R1 and R2. Although the percentage increases in mean arterial pressure after ECT were significantly smaller in groups P (P < 0.01) and R2 (P < 0.05) than in group R1, they did not significantly differ between groups P and R2.
CONCLUSIONS: Divided use of remifentanil at 1 and 2 μg/kg combined with propofol 0.5 mg/kg produces an acceptable outcome in both seizure duration and hemodynamic stability during ECT compared with the standard hypnotic doses of propofol alone or remifentanil 1 μg/kg followed by propofol 0.5 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21116659     DOI: 10.1007/s00540-010-1049-4

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  21 in total

1.  Remifentanil supplementation of propofol during electroconvulsive therapy: effect on seizure duration and cardiovascular stability.

Authors:  Tali Vishne; Stanislav Aronov; Revital Amiaz; Abba Etchin; Leon Grunhaus
Journal:  J ECT       Date:  2005-12       Impact factor: 3.635

2.  Effects of combined methohexitone-remifentanil anaesthesia in electroconvulsive therapy.

Authors:  F A Andersen; D Arsland; H Holst-Larsen
Journal:  Acta Anaesthesiol Scand       Date:  2001-08       Impact factor: 2.105

3.  Risks of general anesthesia and elective operation in the hypertensive patient.

Authors:  L Goldman; D L Caldera
Journal:  Anesthesiology       Date:  1979-04       Impact factor: 7.892

4.  Effects of remifentanil and alfentanil on seizure duration, stimulus amplitudes and recovery parameters during ECT.

Authors:  Z N Akcaboy; E Y Akcaboy; B Yigitbasł; G Bayam; B Dikmen; N Gogus; N Dilbaz
Journal:  Acta Anaesthesiol Scand       Date:  2005-09       Impact factor: 2.105

5.  Seizure duration and clinical effect in electroconvulsive therapy.

Authors:  B M Maletzky
Journal:  Compr Psychiatry       Date:  1978 Nov-Dec       Impact factor: 3.735

6.  Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris.

Authors:  B F Robinson
Journal:  Circulation       Date:  1967-06       Impact factor: 29.690

7.  Propofol reduces seizure duration in patients having anaesthesia for electroconvulsive therapy.

Authors:  K H Simpson; P J Halsall; C M Carr; K G Stewart
Journal:  Br J Anaesth       Date:  1988-09       Impact factor: 9.166

8.  Propofol sparing effect of remifentanil using closed-loop anaesthesia.

Authors:  S E Milne; G N C Kenny; S Schraag
Journal:  Br J Anaesth       Date:  2003-05       Impact factor: 9.166

9.  The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy.

Authors:  M N Avramov; M M Husain; P F White
Journal:  Anesth Analg       Date:  1995-09       Impact factor: 5.108

10.  Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B).

Authors:  P S Glass; D Hardman; Y Kamiyama; T J Quill; G Marton; K H Donn; C M Grosse; D Hermann
Journal:  Anesth Analg       Date:  1993-11       Impact factor: 5.108

View more
  1 in total

Review 1.  Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yoshiteru Takekita; Taro Suwa; Naotaka Sunada; Hirotsugu Kawashima; Chiara Fabbri; Masaki Kato; Aran Tajika; Toshihiko Kinoshita; Toshi A Furukawa; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-01-28       Impact factor: 5.270

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.